pSivida Preparing for NDA, Announcing New Partnerships

Nancy Lurker, president and CEO, reports data from two Phase III trials for Durasert’s use in treating uveitis. The company plans to file an NDA by the end of January. The company also announced new partnerships that will test the microdosing drug delivery technology in other conditions including glaucoma.